LONG ACTING OCTREOTIDE IN PTS WITH DISSEMINATED NEUROENDOCRINE TUMORS

被引：0
|
作者：
Markovich, A. [1 ]
Emelianova, G. [1 ]
Gorbounova, V. [1 ]
Bruzgin, V. [1 ]
Orel, N. [1 ]
机构：
[1] NN Blokhin Russian Canc Res Ctr Ramn, Dept Chemotherapy, Moscow, Russia
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：382 / 382
页数：1
相关论文
共 50 条
  • [1] Octreotide acetate long-acting release in treatment of pancreatic neuroendocrine tumors
    ZHANG ShiLI YuxiuLI NaishiLI WenhuiZHU HuijuanGU Feng and WANG Heng Department of EndocrinologyKey Laboratory of EndocrinologyMinistry of HealthPeking Union Medical College HospitalChinese Academy of Medical Sciences Peking Union MedicalCollegeBeijing China
    中华医学杂志（英文版）, 2009, (13) : 1582 - 1584
  • [2] Octreotide acetate long-acting release in treatment of pancreatic neuroendocrine tumors
    Zhang Shi
    Li Yu-xiu
    Li Nai-shi
    Li Wen-hui
    Zhu Hui-juan
    Gu Feng
    Wang Heng
    CHINESE MEDICAL JOURNAL, 2009, 122 (13) : 1582 - 1584
  • [3] THE USE OF THE LONG-ACTING SOMATOSTATIN ANALOG OCTREOTIDE IN THE TREATMENT OF GUT NEUROENDOCRINE TUMORS
    WYNICK, D
    BLOOM, SR
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 73 (01): : 1 - 3
  • [4] The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: Comparison with standard subcutaneous octreotide therapy
    Dogliotti, L
    Tampellini, M
    Stivanello, A
    Gorzegno, G
    Fabiani, L
    ANNALS OF ONCOLOGY, 2001, 12 : S105 - S109
  • [5] Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide
    Ricci, S
    Antonuzzo, A
    Galli, L
    Ferdeghini, M
    Bodei, L
    Orlandini, C
    Conte, PF
    ANNALS OF ONCOLOGY, 2000, 11 (09) : 1127 - 1130
  • [6] Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors
    Lau, Sally C.
    Abdel-Rahman, Omar
    Cheung, Winson Y.
    MEDICAL ONCOLOGY, 2018, 35 (09)
  • [7] Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors
    Sally C. Lau
    Omar Abdel-Rahman
    Winson Y. Cheung
    Medical Oncology, 2018, 35
  • [8] Prescribing Characteristics of Octreotide Immediate-Release and Long-Acting Release in Patients with Neuroendocrine Tumors
    Cheng, Yue
    Anthony, Lowell
    Delcher, Chris
    Moga, Daniela C.
    Chauhan, Aman
    Huang, Bin
    Adams, Val
    ONCOLOGIST, 2023, 28 (06): : 479 - 485
  • [9] Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors
    Saif, Muhammad Wasif
    Fu, Julie
    Smith, Melissa H.
    Weinstein, Barbara
    Relias, Valerie
    Daly, Kevin P.
    JOURNAL OF PANCREATIC CANCER, 2018, 4 (01): : 64 - 71
  • [10] Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors
    Ayyagari, Rajeev
    Neary, Maureen
    Li, Shang
    Rokito, Ariel
    Yang, Hongbo
    Xie, Jipan
    Benson, Al B., III
    AMERICAN HEALTH AND DRUG BENEFITS, 2017, 10 (08): : 408 - 415
12345